Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Farah Ali

Hospice and Palliative Medicine Covington, LA Medical Doctor

NPI 1528565579 CMS profile 8805332

1010 S Polk St, Covington, LA 70433

Open in the dashboard

General payments

$676

17 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farah Ali of Covington, LA is reported in the CMS Open Payments database as having received $676 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $187 3
2023 General $298 7
2022 General $164 5
2020 General $27 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farah Ali
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Farah Ali were reported at $187. Among 151 Hospice and Palliative Medicine profiles paid that year, the median was $79 and the middle half received between $28 and $179.

Show as a table
Year Farah Ali Hospice and Palliative Medicine median Middle half National median
2019 $0 $70 $20–$164 $163
2020 $27 $67 $19–$171 $114
2021 $0 $81 $22–$170 $132
2022 $164 $92 $29–$229 $149
2023 $298 $98 $33–$185 $160
2024 $0 $68 $24–$170 $164
2025 $187 $79 $28–$179 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $316 9 payments
  2. Janssen Biotech, Inc. $141 1 payment
  3. Janssen Pharmaceuticals, Inc $111 1 payment
  4. Currax Pharmaceuticals LLC $27 2 payments
  5. Merck Sharp & Dohme Corporation $27 1 payment
  6. Medtronic, Inc. $19 1 payment
  7. Lundbeck LLC $19 1 payment
  8. ITI, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $676 17 payments
Products named General payments · program years 2020–2025
  1. VRAYLAR $289 7 payments
  2. RYBREVANT $141 1 payment
  3. SPRAVATO $111 1 payment
  4. CONTRAVE $27 2 payments
  5. SYNTHROID $27 2 payments
  6. VERQUVO $27 1 payment
  7. LAGEVRIO $27 1 payment
  8. INTELLIS ADAPTIVESTIM $19 1 payment
  9. REXULTI $19 1 payment
  10. CAPLYTA $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

419

Median for Internal Medicine: 777

Drug cost

$22,639

Median for Internal Medicine: $73,373

Branded share of claims

38.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 11 $5,565
Xtampza Er Oxycodone Myristate Brand 11 $4,078
Fentanyl Generic 38 $3,838
Oxycodone Hcl Generic 75 $2,383
Morphine Sulfate Er Morphine Sulfate Brand 57 $1,929
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 36 $1,411
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 48 $1,349
Morphine Sulfate Generic 19 $661
Gabapentin Generic 52 $541
Modafinil Generic 16 $341

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$18,884

Medicare's payments for the services billed

Medicare patients

88

Average age 75

Services billed

200

51 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 58%
Arthritis 58%
Ischemic heart disease 55%
Chronic kidney disease 50%
COPD 48%
Heart failure 43%
Diabetes 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record